At the time of writing, ImmunoPrecise Antibodies Ltd [IPA] stock is trading at $0.44, up 2.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The IPA shares have gain 8.03% over the last week, with a monthly amount glided 4.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunoPrecise Antibodies Ltd [NASDAQ: IPA] stock has seen the most recent analyst activity on December 02, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $9. Previously, The Benchmark Company started tracking the stock with Buy rating on October 25, 2021, and set its price target to $12.
For the past year, the stock price of ImmunoPrecise Antibodies Ltd fluctuated between $0.27 and $1.39. ImmunoPrecise Antibodies Ltd [NASDAQ: IPA] shares were valued at $0.44 at the most recent close of the market.
Analyzing the IPA fundamentals
According to ImmunoPrecise Antibodies Ltd [NASDAQ:IPA], the company’s sales were 17.42M for trailing twelve months, which represents an -5.89% plunge. Gross Profit Margin for this corporation currently stands at 0.51% with Operating Profit Margin at -0.55%, Pretax Profit Margin comes in at -2.13%, and Net Profit Margin reading is -1.92%. To continue investigating profitability, this company’s Return on Assets is posted at -1.01, Equity is -1.48 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4233 points at the first support level, and at 0.4027 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4668, and for the 2nd resistance point, it is at 0.4897.
Ratios To Look Out For
It is important to note that ImmunoPrecise Antibodies Ltd [NASDAQ:IPA] has a current ratio of 2.32. On the other hand, the Quick Ratio is 2.11, and the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 1.14, the price to book ratio is 1.17.
